Wire Stories
EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in ?-thalassemia Accepted for Review by China National Medical Products Administration
BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–EdiGene, Inc. ( �Company�, or �EdiGene�), today announced the Center for Drug Evaluation (CDE) of China National Medical...